Last updated: October 12, 2026
Delgocitinib is a topical pan-Janus kinase inhibitor commercialized in Japan as Corectim and approved in the European Union as Anzupgo for moderate-to-severe chronic hand eczema. Its commercial profile is expanding from a Japan-focused atopic dermatitis product into a specialty dermatology asset with European market access. Public filings do not disclose product-level revenue, so delgocitinib sales cannot be isolated reliably from Torii Pharmaceutical’s or LEO Pharma’s consolidated results.
The asset has no U.S. FDA approval, no U.S. Orange Book listing and no biosimilar exposure. Its principal commercial risks are competition from topical ruxolitinib, oral JAK inhibitors, corticosteroids, biologics and nonsteroidal topical therapies. Its principal growth opportunity is chronic hand eczema, where treatment options remain limited and systemic therapy is often undesirable.
What is delgocitinib and how is it commercialized?
Delgocitinib, also known as JTE-052, is a topical small-molecule inhibitor of JAK1, JAK2, JAK3 and TYK2. It suppresses cytokine signaling involved in inflammatory skin disease.
| Product |
Company |
Market |
Indication |
Formulation |
| Corectim |
Torii Pharmaceutical and Japan Tobacco |
Japan |
Atopic dermatitis |
Ointment and cream |
| Anzupgo |
LEO Pharma |
European Union |
Moderate-to-severe chronic hand eczema in adults |
20 mg/g cream |
| Delgocitinib |
LEO Pharma development program |
Selected international markets |
Chronic hand eczema and other inflammatory dermatoses |
Topical cream |
Japan Tobacco discovered delgocitinib and licensed commercial rights outside Japan to LEO Pharma. Torii Pharmaceutical, a Japan Tobacco affiliate, commercializes Corectim in Japan. LEO Pharma leads development and commercialization in Europe and other territories covered by its licensing arrangement.[1][2]
Delgocitinib differs from selective JAK inhibitors because it inhibits multiple JAK family members and is applied locally. The topical route limits systemic exposure relative to oral JAK therapies, although regulators still evaluate class-related safety risks and long-term use restrictions.
When did delgocitinib receive regulatory approval?
Japan approved Corectim ointment for atopic dermatitis in 2020. Later Japanese approvals expanded the product’s formulation and pediatric use. The Japanese label covers topical treatment for atopic dermatitis in defined age groups and body-surface-area limitations.[1]
The European Commission authorized Anzupgo in 2024 for adults with moderate-to-severe chronic hand eczema who have not responded adequately to topical corticosteroids or for whom topical corticosteroids are not advisable.[2]
| Regulatory event |
Timing |
Commercial significance |
| Japanese approval of Corectim ointment |
2020 |
Established first commercial market |
| Japanese expansion into pediatric use and additional formulation options |
2021 onward |
Enlarged addressable patient population |
| Positive Phase 3 DELTA program in chronic hand eczema |
2023 |
Supported European regulatory filing |
| European Union authorization of Anzupgo |
2024 |
Created the first major non-Japanese commercial expansion |
| U.S. FDA approval |
None publicly established through the cited regulatory sources |
No U.S. launch or Orange Book market |
The European approval is strategically important because chronic hand eczema is a distinct commercial opportunity from atopic dermatitis. Patients with chronic hand eczema often cycle through topical corticosteroids, emollients, phototherapy and systemic immunosuppressants. A nonsteroidal topical JAK inhibitor can be positioned between conventional topical treatment and systemic therapy.
How large is the delgocitinib market opportunity?
Delgocitinib addresses two markets with different economics.
Japan is the established revenue base. Corectim competes in atopic dermatitis, a large patient population with substantial generic and branded treatment competition. Reimbursement and physician familiarity support market access, but topical atopic dermatitis therapy is price-sensitive and fragmented across corticosteroids, tacrolimus, crisaborole-type products, topical JAK inhibitors and biologics.
Europe provides a smaller initial indication but a potentially higher-value specialty segment. Anzupgo is directed at moderate-to-severe chronic hand eczema, where disease burden, occupational impairment and treatment failure can support premium pricing.
| Market driver |
Effect on delgocitinib |
| Established Japanese approval |
Reduces launch risk and provides commercial validation |
| European chronic hand eczema indication |
Expands geographic and therapeutic reach |
| Topical administration |
Supports use before systemic immunosuppression |
| Broad JAK mechanism |
May provide activity across inflammatory pathways |
| Safety scrutiny for JAK inhibitors |
Can restrict duration, patient selection and promotional claims |
| Competition from topical ruxolitinib |
Limits differentiation in inflammatory dermatoses |
| Lack of U.S. approval |
Removes the largest potential high-value market from the current base case |
The addressable market is not equivalent to the entire atopic dermatitis or hand eczema population. Delgocitinib is most commercially relevant for patients requiring prescription nonsteroidal therapy, patients with inadequate corticosteroid response, and patients for whom systemic therapy is premature or unsuitable.
What is the financial trajectory for delgocitinib?
Public company reporting does not provide a complete standalone income statement for delgocitinib. Torii reports consolidated financial performance, while LEO Pharma is privately held and does not publish a detailed product-level revenue series for Anzupgo. As a result, a verified annual revenue trajectory for the brand is not publicly available from the cited filings.
The financial trajectory can still be assessed by commercial stage:
| Period |
Financial interpretation |
| 2020 to 2022 |
Japan-only commercialization with revenue dependent on Corectim uptake and label expansion |
| 2023 |
Development investment and launch preparation for European chronic hand eczema |
| 2024 onward |
Potential step-up from European commercialization, but with launch costs, country-by-country reimbursement and physician adoption risk |
| Medium term |
Revenue growth depends on European penetration, additional approvals and possible expansion into other inflammatory skin diseases |
The Japanese business is likely to produce more predictable near-term cash flow because Corectim has an established reimbursement and distribution infrastructure. European revenue should have greater growth leverage but also greater execution risk. National pricing negotiations, tender dynamics, physician prescribing guidelines and reimbursement decisions will determine the speed of uptake.
No publicly disclosed transaction value establishes the royalty rate, milestone schedule or net sales economics between Japan Tobacco, Torii Pharmaceutical and LEO Pharma. Those terms should be treated as confidential commercial provisions rather than modeled from public data.
How does delgocitinib compare with competing drugs?
Delgocitinib versus topical ruxolitinib
Ruxolitinib cream, marketed as Opzelura by Incyte, is a selective JAK1/JAK2 inhibitor. Its principal approved uses include atopic dermatitis and nonsegmental vitiligo in certain jurisdictions. Delgocitinib is a broader pan-JAK inhibitor and has a distinct European chronic hand eczema authorization.
Ruxolitinib has stronger commercial visibility because of U.S. FDA approval and a larger global development infrastructure. Delgocitinib has a more concentrated indication strategy and lacks U.S. market access.
Delgocitinib versus oral JAK inhibitors
Abrocitinib, upadacitinib and baricitinib offer systemic efficacy for atopic dermatitis but carry greater systemic exposure and class-related safety management. Delgocitinib can be used as a topical option for patients who do not require systemic therapy or who have contraindications to oral JAK inhibitors.
The products are more complementary than directly interchangeable. Oral JAK inhibitors are more competitive in severe, widespread disease. Delgocitinib is better positioned for localized or regional disease where topical treatment remains clinically appropriate.
Delgocitinib versus topical corticosteroids and calcineurin inhibitors
Corticosteroids remain the volume standard because of low cost, physician familiarity and broad generic availability. Tacrolimus and pimecrolimus provide nonsteroidal alternatives, particularly in sensitive body areas. Delgocitinib’s commercial case depends on demonstrating better persistence, steroid-sparing value or efficacy in patients who do not respond adequately to these therapies.
What patents protect delgocitinib?
Delgocitinib’s protection is expected to rely on several patent categories rather than a single enforceable right:
- Composition-of-matter patents covering the JAK inhibitor molecule.
- Pharmaceutical composition patents covering topical formulations.
- Method-of-use patents covering atopic dermatitis and chronic hand eczema.
- Formulation and dosing patents covering concentration, vehicle, treatment frequency or patient populations.
- Manufacturing patents covering synthesis, intermediates or impurity control.
The practical value of the estate differs by jurisdiction. Composition patents generally provide the strongest protection, while formulation and method-of-use patents may be easier to design around or challenge. European market protection also depends on regulatory exclusivity, national patent status and any supplementary protection rights.
Because delgocitinib is not FDA-approved, it has no U.S. Orange Book listing. A U.S. generic applicant therefore has no current Orange Book-listed patent set to certify against under the standard abbreviated new drug application pathway.[3]
| Protection category |
Commercial role |
Relative strength |
| Active ingredient |
Blocks direct copying of the molecule |
Highest |
| Topical formulation |
Protects cream or ointment composition |
Moderate |
| Chronic hand eczema method |
Supports indication-specific enforcement |
Moderate to lower |
| Manufacturing process |
Raises technical substitution costs |
Variable |
| Regulatory exclusivity |
Delays reliance on clinical data |
Jurisdiction-specific |
When does delgocitinib lose exclusivity?
A single global loss-of-exclusivity date cannot be assigned without a verified jurisdiction-by-jurisdiction patent family review. The relevant dates will differ between Japan, the European Union, the United Kingdom, the United States and other markets.
Japan’s Corectim product has the longest commercialization history and therefore faces earlier patent-aging pressure than Anzupgo’s newer European indication. European protection may extend beyond the base composition patent through formulation, use claims or supplementary protection mechanisms, but those rights must be validated at the national patent-register level.
The absence of a U.S. approval eliminates immediate U.S. patent-cliff analysis. If LEO Pharma later pursues FDA approval, the U.S. exclusivity profile would depend on the approved indication, listed patents, New Drug Application exclusivity and any pediatric extension.
Are there Paragraph IV challenges or generic launch risks?
No current U.S. Paragraph IV challenge is relevant because delgocitinib lacks an FDA-approved reference product and an Orange Book listing. The near-term generic risk is therefore concentrated in Japan and, later, Europe.
In Japan, generic entry would depend on the surviving composition, formulation and manufacturing claims, as well as Japanese regulatory requirements for topical products. A generic could seek approval after applicable patent barriers expire or could challenge patent validity.
In Europe, generic and hybrid applications may become relevant after the applicable data, market and patent protections expire. Topical products can face technical barriers involving vehicle composition, skin permeation, particle size, manufacturing controls and comparative bioavailability. Those barriers do not guarantee durable protection, but they can delay rapid substitution.
Delgocitinib has no biosimilar risk. It is a small molecule, not a biologic.
What is the FDA and Orange Book status of delgocitinib?
Delgocitinib is not listed as an FDA-approved drug in the Orange Book based on the cited regulatory sources. There is no established U.S. reference listed drug, no U.S. NDA exclusivity period and no approved U.S. topical product under the delgocitinib name.[3]
This creates both a disadvantage and an option value. The disadvantage is the absence of U.S. revenue. The option value is that a successful U.S. development program could materially enlarge the commercial opportunity, particularly for chronic hand eczema or atopic dermatitis. The cost would include new U.S. clinical, regulatory and market-access investment.
Which companies are challenging delgocitinib commercially?
| Competitor |
Product or class |
Competitive pressure |
| Incyte |
Opzelura, topical ruxolitinib |
Closest branded topical JAK competitor |
| AbbVie |
Rinvoq, upadacitinib |
Systemic efficacy in moderate-to-severe atopic dermatitis |
| Pfizer |
Cibinqo, abrocitinib |
Oral JAK alternative |
| Sanofi and Regeneron |
Dupixent, dupilumab |
Established biologic for atopic dermatitis |
| Leo Pharma and generic manufacturers |
Corticosteroids and dermatology products |
Low-cost standard treatment |
| Tacrolimus and pimecrolimus manufacturers |
Topical calcineurin inhibitors |
Nonsteroidal alternatives |
The main commercial distinction is treatment position. Delgocitinib is not competing only on efficacy. It is competing on topical convenience, steroid-sparing potential, avoidance of systemic exposure and suitability for chronic hand eczema.
What is the litigation and settlement outlook?
No major U.S. patent litigation or Paragraph IV settlement is associated with delgocitinib because the product has no FDA-approved U.S. reference listing. European and Japanese disputes would be more likely to involve national validity, infringement, reimbursement or regulatory approval issues.
Potential litigation targets include:
- Validity of composition patents.
- Scope of topical formulation claims.
- Enablement and written-description issues for broad inflammatory-disease claims.
- Obviousness of using known JAK inhibition in chronic hand eczema.
- Generic or hybrid-product equivalence.
- National enforcement of European patents after grant.
No publicly disclosed settlement agreement is identified in the cited sources.
How strong is the delgocitinib commercial and patent estate?
The commercial estate is moderate and improving. Japan provides an established base, while European approval creates a second platform. The absence of U.S. approval materially limits current global value.
The patent estate is potentially strongest around the active ingredient and weakest around broad method-of-use claims. Formulation patents can extend differentiation but are vulnerable to alternative vehicles and concentration changes. The overall exclusivity position should therefore be modeled as a layered portfolio rather than a single patent expiry.
Key Takeaways
- Delgocitinib is a topical pan-JAK inhibitor marketed in Japan as Corectim and in the EU as Anzupgo.
- Japan is the established commercial market; Europe is the principal expansion market.
- The European indication targets moderate-to-severe chronic hand eczema in adults.
- Public filings do not disclose standalone delgocitinib revenue or licensing economics.
- Delgocitinib has no FDA approval, no Orange Book listing and no current U.S. Paragraph IV exposure.
- The main competitors are topical ruxolitinib, oral JAK inhibitors, biologics, corticosteroids and calcineurin inhibitors.
- Generic risk is jurisdiction-specific and depends on composition, formulation, use and manufacturing patents.
- Delgocitinib has no biosimilar risk because it is a small molecule.
- Revenue growth depends on European reimbursement, chronic hand eczema adoption and future geographic or indication expansion.
FAQs
Is delgocitinib approved for atopic dermatitis in the United States?
No. Delgocitinib does not have an established FDA approval or Orange Book listing in the cited regulatory record.
What is the brand name for delgocitinib in Japan?
The Japanese brand is Corectim. It is commercialized by Torii Pharmaceutical, a Japan Tobacco group company.
What is the European brand name for delgocitinib?
The European brand is Anzupgo. It is approved for adults with moderate-to-severe chronic hand eczema under specified treatment conditions.
Is delgocitinib a biologic or a small molecule?
Delgocitinib is a synthetic small-molecule JAK inhibitor. It is not a biologic and cannot be challenged through a biosimilar pathway.
What is the most important commercial risk for delgocitinib?
The main risk is competitive displacement by established topical and systemic therapies before delgocitinib achieves broad reimbursement and physician adoption outside Japan.
References
-
Pharmaceuticals and Medical Devices Agency. (2020). Review report: Delgocitinib topical preparations. Japan Ministry of Health, Labour and Welfare.
-
European Medicines Agency. (2024). Anzupgo: EPAR - product information and assessment report. European Union.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
LEO Pharma. (2023). LEO Pharma announces positive Phase 3 results for delgocitinib cream in chronic hand eczema. Company announcement.
-
Torii Pharmaceutical Co., Ltd. (2024). Integrated report and financial results. Tokyo.
